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Purpose: This is a proof-of-principle study investigating the feasibility of using late gadolinium
enhancement magnetic resonance imaging (LGE-MRI) to detect left atrium (LA) radiation damage.
Methods and materials: LGE-MRI data were acquired for 7 patients with previous external beam
radiation therapy (EBRT) histories. The enhancement in LA scar was delineated and fused to the
computed tomography images used in dose calculation for radiation therapy. Dosimetric and
normal tissue complication probability analyses were performed to investigate the relationship
between LA scar enhancement and radiation doses.
Results: The average LA scar volume for the subjects was 2.5 cm3 (range, 1.2-4.1 cm3; median,
2.6 cm3). The overall average of the mean dose to the LA scar was 25.9 Gy (range, 5.8-49.2 Gy).
Linear relationships were found between the amount of radiation dose (mean dose) (R2Z 0.8514,
PZ .03) to the LA scar-enhanced volume. The ratio of the cardiac tissue change (LA scar/LA
wall) also demonstrated a linear relationship with the level of radiation received by the cardiac
tissue (R2Z 0.9787, P < .01). Last, the normal tissue complication probability analysis
suggested a dose response function to the LA scar enhancement.
Conclusions: With LGE-MRI and 3-dimensional dose mapping on the treatment planning system,
it is possible to deﬁne subclinical cardiac damage and distinguish intrinsic cardiac tissue change
from radiation induced cardiac tissue damage. Imaging myocardial injury secondary to EBRT
using MRI may be a useful modality to follow cardiac toxicity from EBRT and help identify
individuals who are more susceptible to EBRT damage. LGE-MRI may provide essentialConﬂicts of interest: None.
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creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionRadiation-induced heart damage from treatment of left
breast cancer,1,2 esophagus,3-5 and lymphoma6-12 have
been reported for decades. Some of the common late effects
of cardiac toxicity include pericarditis, coronary artery
disease, or myocardial infarction.13 With the improvement
of treatment techniques, 3-dimensional (3D) imaging and
planning systems, advancement in treatment technologies
(eg, intensity modulated radiation therapy), and imple-
mentation of active breathing control during radiation
treatment, radiation dose delivered to the heart has been
signiﬁcantly reduced in recent years. In spite of these ad-
vances, in many clinical scenarios the heart still receives a
signiﬁcant dose from radiation treatment of common can-
cers such as lung, esophagus, breast, and lymphoma.
The consensus constraint dose to the heart for different
treatment sites is still not precisely determined. Different
institutions and clinical trials often use varying heart dose
limitations in radiation treatment delivery. One of the
biggest challenges of deﬁning radiation induced cardiac
injury relative to radiation dose is the difﬁculty in delin-
eating the clinically relevant subregions of the heart from
planning computed tomography (CT) images. To study
the radiation dose effect to the heart, many studies have
contoured the entire heart, pericardium, or the left
ventricle alone as the volumes of interest for consider-
ation.3,5,14,15 Various imaging modalities can be used in
investigating radiation-induced heart disease (RIHD).16
Echocardiography is useful in understanding the size
and shape of the heart, pumping performance and valvular
disease severity evaluation. Nuclear cardiology can pro-
vide valuable information to assess blood ﬂow, the
pumping function of the heart, and the size of the heart,
which enable the assessment of the disease extent and the
prediction of outcomes. However, both echocardiography
and nuclear cardiology do not offer detail anatomical
information. Cardiac CT offers anatomical information on
the heart and its vicinity; CT angiogram provides further
detail pictures of the blood vessels that go to the heart.
One of the main concerns about CT is the radiation
exposure; it is also difﬁcult to deﬁne clinical relevant
subregions of the heart. We had chosen cardiac magnetic
resonance imaging (MRI) because it is widely recognized
as one of the most useful, noninvasive imaging modalities
for cardiac structures, including assessment of cardiac
volumes, systolic function, and evaluation of tissue
structural remodeling (referred to as ﬁbrosis).16 Specif-
ically, late gadolinium enhancement (LGE)-MRI is aunique imaging protocol that can be used to identify
infarcted myocardial tissue and provide ﬁbrosis assess-
ment. Myocardial ﬁbroses had been found to be one of the
most common histologic features of the failing heart and a
major independent predictive factor of adverse cardiac
outcome from previous studies.17 In the LGE-MRI,
infarcted or ﬁbrotic tissue appears with bright contrast,
and studies have shown links between the amount of LGE
in the myocardial tissue and prognosis in patients with
cardiomyopathy.18-22 Fallah-Rad et al23 established the
utility of LGE-MRI to identify myocardial changes (focal
LGE in the left ventricle) in a group of breast cancer
patients who experienced trastuzumab-induced cardio-
myopathy. We believe that LGE-MRI can also offer
important information for patient with external beam ra-
diation therapy (EBRT) history. To date, the relationship
between the dose from thoracic EBRT and the extent of
LGE presentation has not been described.
In this study, we explore the potential of LGE-MRI to
detect EBRT-induced injury to the left atrium. We
hypothesize that LGE-MRI can detect the amount of
ﬁbrosis (myocardial tissue injury) in patients with previ-
ous EBRT history, and that a dose-response relationship
between EBRT dose and EBRT-induced tissue injury can
be deﬁned.Methods and materials
Patients
Seven patients with previous thoracic EBRT history
(6 with lymphoma, 1 with an esophageal diagnosis), with
3.1  1.9 elapsed years between EBRT and LGE-MRI
acquisition were studied. The demographic information
and radiation treatment history of the study subjects are
presented in Table 1. All 6 of the lymphoma patients had
exposure to anthracyclines. Two lymphoma patients had
Hodgkin’s lymphoma: 1 was treated with Stanford V and
the other had early-stage disease and was treated with
2 cycles of Adriamycin-bleomycin-vinblastine sulfate-
dacarbazine. Four lymphoma patients had diffuse large
B-cell lymphoma and all had 6 cycles of rituximab-
cyclosphosphamide-hydroxyldaunorubin-oncovin-predni
sone. No patient had a previous heart condition. One
patient had esophagus cancer and did not have exposure
to anthracyclines. He was treated on a Radiation Therapy
Oncology Group protocol and received chemoradiation
Table 1 Patient characteristics
Patient
no.
Age (at time of
RT/MRI)
Lapsed time
(y)a
Treatment site, technique Prescribed
dose (Gy)
Treatment
fractionation
Chemotherapy regimen
1 33/33 0.2 Left neck and mediastinum,
AP/PA
20.0 10 ABVD 2
2 31/35 4.4 Mediastinum, AP/PA 30.6 17 R-CHOP 6
3 55/59 3.2 Right heart, 3D-CRT with
oblique ﬁelds
30.6 17 R-CHOP 6 with IT
methotrexate
4 26/29 3.6 Mediastinum, AP/PA 36.0 20 Stanford V, ICE, BEAM
5 41/48 6.6 Mediastinum, LAO/RPO 36.0 20 R-CHOP 6
6 58/61 2.4 Modiﬁed mantle, AP/PA 36.0 20 R-CHOP 6 with IT
methotrexate
7 72/74 1.5 Esophagus, 4-ﬁeld box 54.3 28 Cisplatin, paclitaxel, and
cetuximab
Average 45/48 3.1 - 34.8 18.9
ABVD, Adriamycin-bleomycin-vinblastine sulfate-dacarbazine; AP, anteroposterior; BEAM, BCNU, etoposide, cytarabine, and melphalan; 3D-CRT,
3-dimensional conformal radiation therapy; ICE, ifosfamide, carboplatin, etoposide; LAO, left anterior oblique; MRI, magnetic resonance imaging;
PA, posteroanterior; R-CHOP, rituximab-cyclosphosphamide-hydroxyldaunorubin-oncovin-prednisone; RPO, right posterior oblique; RT, radiation
therapy.
a Lapsed time was the time between RT computed tomography simulation and late gadolinium enhancement-MRI dates.
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from our institution, and the study protocol was reviewed
and approved by the Institutional Review Board and
was Health Insurance Portability and Accountability
Actecompliant.MRI acquisition and cardiac analysis
LGE-MRI data were acquired on a Siemens Verio
3-Tesla MRI scanner (Siemens Medical Systems, Erlan-
gen, Germany). The LGE imaging was acquired using a
respiration- and electrocardiogram-gated gradient echo
pulse sequence. Detailed parameters for LGE images have
been previously publised.24,25 Depending on heart rate
and respiratory pattern, overall scanned time for the LGE-
MRI study was 4-8 minutes.
The analysis of the 3D LGE images was performed
using our custom software, Corview44 (MARREK Inc.,
Salt Lake City, UT), a cardiac MRI analysis interface.
Left and right atrial endocardial borders were manually
contoured to delineate the left and right atrial walls on the
3D LGE-MRI. The contouring was performed to conﬁne
the region of interest to the wall alone, thereby avoiding
the blood pool. Wall segmentation was deﬁned as the
endocardial segmentation subtracted from the epicardial
segmentation. To delineate enhancement in atrial walls, a
relative intensity threshold was established by an imaging
expert who was blinded to the dose distribution infor-
mation (eg, pixel intensity more than 3 standard
deviations above the intensity found in the normal tissue).
The deﬁned enhanced areas were then veriﬁed indepen-
dently to ensure the appropriateness of lesion detection.A detailed description of atrial wall enhancement delin-
eation can be found in the published manuscript.24Image registration and dose mapping
All EBRT treatment plans used for previous radiation
treatment of the patient were developed in the Eclipse
10.0 (Varian Medical System, Palo Alto, CA) treatment
planning system (TPS). We imported 3D LGE-MRI with
delineated atrial walls and scars of these patients into the
Eclipse TPS. 3D CT images with 1 second rotation time
were acquired at the time of simulation and were regis-
tered with the delineated 3D LGE-MRI (rigid registra-
tion). The 3D/3D rigid registrations were performed by
the same medical physicist for all data sets and veriﬁed
by a second medical physicist. The registration process
used auto-matching with Mutual Information,26,27 with
region of interest areas speciﬁed at the heart, followed by
manual match (translate/rotate) to ﬁne tune the ﬁnal
registration. Figure 1 shows a representative image set
and the registered result with the atrial wall designated
as the region of interest, along with MRI-delineated
structures.
Once images were registered, 2 structures were
deﬁned, LA scar and LA wall, based on the LA scar and
LA wall delineations shown on the 3D LGE images. In 6
of the patients we studied, we also delineated right atrium
(RA) scar and RA wall to investigate whether a rela-
tionship can be found between RA scar volume and
radiation doses. One patient did not have RA structure
delineation and therefore was excluded from this part of
the study. After identifying LA/RA scar and LA/RA wall,
Figure 1 (A) Late gadolinium enhancement magnetic resonance imaging (LGE-MRI) with masked structures. Red arrow, left atrium
(LA) scar (white structure); green arrow, LA wall (light gray structure); blue arrow, LA blood pool (darker gray). (B) Computed to-
mography scan taken at the time of simulation for treatment planning showing the same region of interests as the LGE MRI. (C) Rigid
computed tomography/MRI registration results with split window view. Red arrow, LA scar; blue arrow, LA blood pool.
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dose-volume histogram (DVH) data from the TPS.
Dosimetric analysis
Doses received by both structures were visualized on
multiple transverse viewing planes (Fig 2), and quantiﬁed
by DVH. The dose parameters obtained from the DVHFigure 2 Treatment plan showing isodose distribution for
treatment of the esophagus using 3-dimensional conformal four
ﬁeld technique overlaid on blended computed tomography/
magnetic resonance imaging. Red arrow, left atrium scar; blue
arrow, left atrium blood pool; green arrow, left atrium wall.analysis included minimum dose (Dmin), maximum dose
(Dmax), and mean dose (Dmean). We studied the rela-
tionship between the dose received by the LA scar and the
amount of LA scar in 2 ways: ﬁrst, by observing the
relationship between Dmean versus LA scar volume, and,
second, by characterizing and record the LA scar/LA wall
ratio versus dose magnitude. This was done by obtaining
the amount of LA wall and LA scar volume that were
irradiated by different dose levels (<5 Gy, 5-<10 Gy,
10-<15 Gy, 15-<20 Gy, and >20 Gy), and the percent-
age of the LA scar/LA wall were recorded according to
their dose levels from all patients (Fig 3). Additionally, all
radiation doses were also converted to equivalent dose
delivered in 2-Gy per fraction (EQD2) for comparison
purposes. Because RIHD is considered a late effect,
typical choices of alpha/beta ratio range between 2
and 3.3,14,28,29 We therefore chose to use an alpha/beta
ratio of 2.5 for calculation of bio-doses EQD2.Normal tissue complication probability analysis
Normal tissue complication probability (NTCP) is
deﬁned as the probability of a deﬁned complication
occurring in patients because of radiation treatment. For
our purposes, it was deﬁned as the generation of scar
Figure 3 Left atrium (LA) wall and LA scar 3-dimensional display in different dose levels to demonstrate higher dose level resulted in
higher percentage of LA scar/LA wall ratio for 1 of the cases. The heart is shown in dark gray line; LA wall in light green; LA scar in
magenta. (A) The amount of LA wall and LA scar that were irradiated with 10 Gy; LA scar/LA wall: 17.3%. (B) The amount of LA wall
and LA scar that were irradiated with 30 Gy; LA scar/LA wall: 22.0%.
Table 2 Dosimetric Results for LA scar and RA scar
Patient
no.
Scar
(cm3)
Dmin
(Gy)
Dmax
(Gy)
Dmean
(Gy)
LA scar
1 1.2 0.51 16.21 5.80
2 1.3 4.13 25.04 19.83
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used for calculating NTCP have been previously pub-
lished.30-32 Brieﬂy, NTCP for all patients were calcu-
lated based on the DVH plot to LA scar volume. The
calculation of NTCP was performed using the CERR
toolkit.33 Parameters used for the evaluation were TD50
Z 70.3 Gy, r Z 0.96, and s Z 1, according to Eriks-
son.28 We then evaluated the relationship between
NTCP and our studied complication, LA scar, to deter-
mine if a correlation existed.
Statistical analysis
All statistical tests were conducted using Microsoft
Ofﬁce Excel 2010 (Redmond, WA). We used regression
analysis in this study to observe the relationship between
different parameters. Any resulting R square >0.8 was
considered to be in a linear relationship.3 1.4 1.02 30.30 6.28
4 2.6 5.11 37.29 32.03
5 3.1 7.97 39.27 35.83
6 3.6 3.67 36.92 32.09
7 4.1 5.97 58.84 49.25
Average 2.5 4.05 34.84 25.87
RA scara
1 2.9 0.28 18.40 10.76
2 0 2.30 32.50 17.79
3 0.6 4.37 32.53 17.04
4 0 5.11 37.29 32.03
5 0 21.34 21.92 21.65
6 1.1 2.65 33.53 19.60
Average 0.76 11.06 29.16 18.81
Dmax, maximum dose; Dmean, mean dose; Dmin, minimum dose;
LA, left atrium; RA, ﬁght atrium.
a Only the initial 6 patients received analysis on RA scar.
Because our early results from RA did not demonstrate an obvious
trend with radiation doses, we excluded further RA analysis for
patient number 7.Results
We did not observe any focal left or right ventricle
myocardial injury; we also noted a more signiﬁcant
enhancement in the LA that was absent in the RA. No
relationship can be established between RA scar and
radiation dosage.
Depending on the treatment site, the radiation therapy
prescribed dose to the 7 patients we studied ranged
between 20 and 54.3 Gy, with an average of 34.8 Gy, in
10-28 fractions. The dosimetric parameters we collected,
by patient, are listed in Table 2. The average LA scar
volume for all subjects was 2.5 cm3 (range, 1.2-4.1 cm3;
median, 2.6 cm3); the average RA scar volume for 6
patients was 0.76 cm3 (range, 0-2.9 cm3; median, 0.3
cm3). The average of Dmean to the LA scar was 25.9 Gy
(range, 5.8-49.2 Gy) and for RA scar was 18.8 Gy (range,1.1-35.7 Gy). Three of the cases (patients 1, 4, and 5) had
zero RA scar volume, and the largest RA scar volume was
not originated from the highest Dmean value. Because no
obvious pattern was found in the relationship between RA
scar volume and Dmean, no further dosimetric evaluation
was performed for RA scar. The results for bio doses
(EQD2) for minimum, maximum, and mean doses to LA
scar, and NTCP are given in Table 3. No correlation was
found between the age of the patient, either at time of RT
(R2Z 0.423, PZ .114) or at time of MRI (R2Z 0.408,
PZ .123), and the LA scar amount. There was also no
Table 3 EQD2 and NTCP results
Patient
no.
LA
scar
(cm3)
EQD2-
Dmin
(Gy)
EQD2-
Dmax
(Gy)
EQD2-
Dmean
(Gy)
EUD
(Gy)
NTCP,
%
1 1.2 0.29 14.84 3.97 5.64 16.91
2 1.3 2.51 22.11 16.16 19.52 22.63
3 1.4 0.58 28.83 4.00 5.89 17.01
4 2.6 3.13 36.17 29.20 26.16 25.71
5 3.1 5.13 38.95 34.17 36.57 30.94
6 3.6 2.19 35.66 29.27 32.17 29.67
7 4.1 3.60 60.16 46.61 50.89 38.80
Dmax, maximum dose; Dmean, mean dose; Dmin, minimum dose;
LA, left atrium; RA, ﬁght atrium.
Figure 5 Scatter plot of equivalent dose delivered in 2-Gy per
fraction (EQD2)-mean dose (Dmean) versus left atrium (LA)
scar volume.
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scar volume (R2Z 0.004, PZ .894).
The scatter plot of Dmean versus LA scar volume
(Fig 4A) and EQD2-Dmean versus LA scar volume
(Fig 5) both showed linear relationships (R2Z 0.851 and
0.864, PZ .003 and .002, respectively). Figure 4B was a
scatter plot of Dmean versus RA scar volume, in which no
obvious relationship was found. The linear relationship
in Figs 4A and 5 suggested that increasing Dmean or
EQD2-Dmean results in a higher volume of cardiac tissue
changes as deﬁned by 3D LGE-MRI. When looking at the
change in ratio of LA scar/LA wall as a function of 5
dose level groups, <5 Gy, 5-10 Gy, 10-15 Gy, 15-20 Gy,
and >20 Gy, a linear relationship was found between
the dose level and the ratio of LA scar/LA wall (Fig 6)
(R2Z 0.9787, P < .01). NTCP results are listed in
Table 3 and plotted against the scar volume (Fig 7). TheFigure 4 Scatter plot of (A) Dmean versus left atrium (LA)
scar volume. (B) Dmean versus right atrium (RA) scar volume.relationship between NTCP and LA scar volume was also
shown to be relatively linear (R2Z 0.883, P < .01),
suggesting a dose response function.Discussion
We evaluated the use of LGE-MRI to detect EBRT-
induced injury in cardiac tissue and found a signiﬁcantly
greater degree of LGE-MRIeindicated myocardial injury
in radiation areas treated with higher doses (P < .01). In
this study, we found a signiﬁcant relationship between LA
scar appearance in LGE-MRI versus patients with EBRT
history, regardless of the elapsed time between EBRT and
LGE-MRI acquisition. Other cardiac risk factors, such as
gender, race, and smoking history were not taken into
consideration relative to the amount of cardiac tissue injury.
Previous studies of RIHD have shown that the incidence of
heart damage varies with the dose, fractionation, and irra-
diated volume of the heart.1,34-37 Many of these studies
typically used symptomatic cardiac disease as the study end
point. However, to be able to accurately describe the risk of
long-term radiation-induced heart injury for patients who
previously underwent EBRT, it is important to have an
early response indicator of damage. To our knowledge, this
is the ﬁrst study to link LGE-MRI delineated myocardial
changes to EBRT cardiac doses. In this pilot study, we
were able to show in 7 patients a near linear dose response
between Dmean and LA scar volume (R2Z 0.8514,
PZ .03). Our results correlate well with Darby et al’s
recent study, which used symptomatic cardiac disease as
the evaluation parameter.29 Darby looked into patients with
invasive breast cancer with EBRT history who experienced
major coronary events (ie, diagnosis of myocardial infrac-
tion, coronary revascularization, or death from ischemic
heart disease) to analyze the effect of RIHD. Darby’s result
showed a linear increasing risk of major coronary event
with radiation exposure. Other previous studies have also
documented increasing cardiovascular disease with
increasing EBRT doses.16
To evaluate patients for cardiac late effects post-
EBRT, various screening and diagnostic tests have been
Figure 6 Relationship between dose level and the percentage
of cardiac tissue change (left atrium [LA] scar/LA wall). The
data shown were in 5 dose level groups: 5 Gy, 5-10 Gy, 10-15
Gy, 15-20 Gy, and 20 Gy. The resulting average cardiac tissue
changes were 12.06% (95 conﬁdence interval [CI], 9.45-
14.67%), 19.48% (95 CI, 12.27-26.67%), no data available for
dose level of 10-15 Gy, 26.33% (95 CI, 21.48-31.18%), and
32.56% (95 CI, 27.73-37.39%), respectively.
Figure 7 Scatter plot of normal tissue complication proba-
bility (NTCP) result versus left atrium (LA) scar volume.
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proﬁle, exercise stress test, cardiac MRI, cardiac CT, and
echocardiogram.16,38 The general consensus dose of
concern identiﬁed in these studies was a heart dose of
more than 30 Gy (without chemotherapy) or with frac-
tionated dose of more than 2 Gy.16,39,40 Furthermore,
Darby et al looked into risk of ischemic heart disease after
breast radiation therapy and concluded that was an
increasing magnitude of the risk of 7.4% per Gray with no
apparent threshold below which there was no risk. Many
of the previous studies evaluated RIHD using different
imaging modalities to detect functional abnormalities,
without correlation of the actual radiation treatment vol-
ume.41-45 Our results also show the same trend of higher
radiation damage with increasing dose. LGE-MRI with
registered radiation dose map may provide more infor-
mation in future detection of RIHD at even lower doses.
Furthermore, it may be able to distinguish intrinsic sub-
clinical damage to the LA wall from actual radiation
damage, as shown in Fig 6, where approximately 11% of
cardiac tissue change was found when extrapolating dose
level to 0 Gy. More data will need to be collected to
conﬁrm this hypothesis. With guidelines for cardiac effect
after RT still being inconclusive, subclinical ﬁndings such
as this one will help distinguish those who need close
follow up post-RT from those who may be at relatively
low risk. Current practice in close long-term follow-up is
a thorough evaluation of new cardiopulmonary symptoms
that should still be followed closely post-ERBT.Study limitations
A primary limitation of this study is the sample size. As
stated previously, this studywas designed as a pilot study to
determine the feasibility of using LGE-MRI to detect LAradiation damage for patients with EBRT history. We are
currently planning the collection of more patient data post-
EBRT to establish a better understanding of the precise
relationship between LGE and EBRT dose. We also intend
to differentiate other risk factors, such as age, gender,
previous cardiac history, type of cancer, and concurrent
chemotherapy. Furthermore, a pre-EBRT and/or pre-
chemotherapy LGE-MRI acquisition for each patient under
investigation should provide better information in estab-
lishing baseline. Regarding our image registration meth-
odology, we used CT-MRI rigid image registration, which
may be limited in ability to account for changes associated
with long elapsed time between the 2 imaging modalities.
To better address uncertainties that arise from positioning,
motion, body shape change, and subjectivities, we plan to
investigate deformable image registration for future
studies. Other technical aspects, such as the spatial reso-
lution in our CT dose mapping process was also limited.
Depending onCTﬁeld of view settings, the pixel sizes from
the seven patients studied ranged from 0.93 mm to
1.27 mm. With 2.5 mm slice thickness, the range of the
voxel sizes of CT were 2.16-4.03 mm3. These voxel size
values are the smallest unit that can be accounted for in the
TPS for dose calculation. As these values varied by patients
according to their CT acquisition parameters, a standard
protocol should be applied in the future for all of the patients
under study. Finally, a histological/MRI correlation would
add credibility by determining the speciﬁc tissue changes
following EBRT-related injury, and will be the subject of
further study.
Conclusions
In conclusion, it was demonstrated in this study that
LGE-MRI can be used in detecting EBRT-induced
myocardial tissue injury and the EBRT dose relation-
ship with the left atrium tissue injury can be established.
These ﬁndings may have important implications for
survivors of thoracic neoplasms including lymphoma,
esophageal, breast, and lung cancers. Imaging myocardial
injury secondary to EBRT using MRI may be a useful
Advances in Radiation Oncology: AprileJune 2016 LGE-MRI detects radiation cardiac damage 113modality for following cardiac toxicity from EBRT, and
in helping identify individuals who are more susceptible
to EBRT damage. LGE-MRI may provide essential in-
formation to identify early screening strategies for
affected cancer survivors after EBRT treatment. Further
research is needed in LGE-MRI before this technique is
applicable to routine clinical practice. Radiation-induced
cardiac injury results in signiﬁcant morbidity and mor-
tality.30 In 1 recent study of more than 40,000 esophagus
patients, on multivariate analysis, radiation therapy was
predictive of death from heart disease (hazard ratio, 1.46;
P < .05) compared with patients that did not receive ra-
diation therapy.46 An early response indicator such as
LGE-MRI may permit us to intervene in patients that
receive a signiﬁcant cardiac dose such as certain lung,
esophagus, breast, and lymphoma patients. It is plausible
that lifestyle interventions and medical therapy could help
ameliorate the radiation therapyeinduced damage.References
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